Author | Karen Sandrick

Articles

Evidence grows for value of high-field MRI in prostate cancer Rx strategy

April 24, 2009

VIENNA-Image-guided intensity-modulated radiotherapy, high-intensity focused ultrasound, and cryotherapy are increasing the curative treatment options for men with prostate cancer. The problem is how to determine which patients are most suitable for these therapies.

Drug-safety experts call for consortium to oversee adverse reactions information

February 24, 2009

CHICAGO-Serious and fatal drug reactions tripled between 1998 and 2005, according to a 2007 FDA analysis. In that time period, the total number of serious adverse drug events multiplied 4 times faster than the number of prescriptions written. The number of serious drug reactions for biotechnology agents rose nearly 18-fold (T Moore et al: Analysis of FDA reported post marketing ADR database, Arch Intern Med 167:1752-1759, 2007).

Payer’s budget to get right targeted drug to right patient

September 02, 2008

When laboratory tests are inaccurate or misinterpreted, patients may receive costly targeted drugs that provide no benefit. If the medical community doesn’t resolve the problem, payers will take action on their own.

High cost of biologics takes a toll on hem/onc practices

August 02, 2008

The difficulty of manufacturing new chemotherapeutic agents-particularly specially formulated biologic cytotoxins-escalates the financial outlay that must be made by physicians as well as driving up the cost of drug delivery to patients, said Howard A. Burris III, MD, chief medical officer and director of drug development at the Sarah Cannon Research Institute and associate with Tennessee Oncology, both in Nashville.